China Medical Device Sales Representative Compliance: 2026 Guide
Will China's 2026 Medical Representative Management Measures apply to medtech field teams? Learn how device and IVD firms should prepare for upcoming rules.
Executive Summary: The 2026 Compliance Signal
On August 1, 2026, China's new Medical Representative Management Measures (NMPA Announcement No. 42 of 2026) will officially take effect. Jointly signed by seven powerful state departments—including the National Medical Products Administration (NMPA), the Ministry of Public Security (MPS), the National Health Commission (NHC), and the State Administration for Market Regulation (SAMR)—the Measures establish a strict, unified filing and behavior management system for healthcare promotion personnel.
For global medical device, in vitro diagnostics (IVD), and combination product manufacturers, the immediate question is clear: Do these measures legally apply to medical device representatives today, and must field teams file on the national platform?
The short answer is no, not yet. The official text contains a clear carve-out clause specifying that personnel rules for medical device enterprises and their in-hospital academic-promotion representatives will be "formulated separately" (另行制定).
However, treating this carve-out as a reason for complacency is a high-risk commercial mistake. The 2026 pharma Measures provide the exact blueprint for the forthcoming medical device personnel rules. Furthermore, provincial authorities are already sweeping medical device representatives into hospital reception and registration systems. Global compliance, market access, and commercialization teams must use this transition window to prepare. This guide details the regulatory boundary of the 2026 Measures, analyzes the core prohibitions, and provides a low-regret preparation roadmap for medtech manufacturers.
Do the 2026 Measures Apply to Medical Device and IVD Representatives?
To evaluate the legal scope of the new framework, manufacturers must inspect NMPA Announcement No. 42 of 2026 alongside its official policy interpretations.
The Measures repeal the Interim Measures for the Filing Administration of Pharmaceutical Representatives (which had been in effect since December 1, 2020) and replace them with a significantly more stringent joint-enforcement mechanism. The signing authorities represent a complete cross-agency enforcement chain:
- National Medical Products Administration (NMPA) (Lead regulator)
- Ministry of Public Security (MPS) (Criminal enforcement)
- National Health Commission (NHC) (Hospital and healthcare professional supervision)
- State Administration for Market Regulation (SAMR) (Anti-monopoly and anti-bribery watchdog)
- National Healthcare Security Administration (NHSA) (Medical insurance fund supervision)
- National Administration of Traditional Chinese Medicine
- National Disease Control and Prevention Administration
The Device Carve-Out Clause
The scope of the new framework is explicitly bounded in the announcement itself. The official text of NMPA Announcement No. 42 of 2026 states:
“规范医疗器械生产经营企业管理其聘用在医疗机构从事医疗器械产品信息传递、沟通、反馈等学术推广活动专业人员的文件另行制定。”
(Translation: "The documents regulating the management by medical device production and operating enterprises of the professionals they employ to conduct academic promotion activities — transmitting, communicating, and feeding back medical device product information — within medical institutions shall be formulated separately.")
Because of this clause, medical device, IVD, and equipment field personnel are not currently required to register or upload their credentials to the national pharmaceutical representative filing platform. Attempting to file device representatives on the current platform is neither legally required nor technically possible, as the platform is structured around drug approval numbers and pharmaceutical Marketing Authorization Holders (MAHs).
Why Medical Device Rules Are on the Horizon
Chinese legal experts and industry associations confirm that the NMPA is actively drafting the companion medical device representative measures. The medical representative measures serve as the template for the entire life sciences commercial sector.
Historically, Chinese healthcare compliance campaigns have followed a pattern: a policy is first trialed and refined in the pharmaceutical sector, and then extended with minor modifications to the medical device and IVD sectors. Given the NMPA's emphasis on clean procurement and anti-corruption across all medical sectors, device manufacturers should expect the device-specific measures to mirror the pharma measures' core pillars:
- Mandatory filing of representative identities and academic credentials.
- MAH principal responsibility for the actions of both direct employees and contracted third parties.
- Strict segregation of academic promotion from commercial sales transactions.
- Hospital-level reception protocols (the "Three-Fixed, Three-Haved" standard).
For comparison with global regulatory structures, manufacturers can look at the US Sunshine Act and Open Payments for device companies. While the US system focuses primarily on post-fact transparency reporting of financial transfers, China’s system goes much further, establishing pre-market filing requirements and strict operational limits on what representatives can do inside hospital walls.
The Nine Prohibited Representative Behaviors
Article 24 of the 2026 Measures establishes the core code of conduct for representatives. For medical device and IVD manufacturers, these nine prohibitions represent the minimum compliance baseline that field teams must follow.
| Prohibited Behavior (Article 24) | Operational Context for Medtech Field Teams |
|---|---|
| 1. Bearing sales tasks, collecting payments, or handling invoices | Field representatives must focus solely on academic and technical support. They must not carry commercial revenue quotas, collect payments, or deliver purchase/sale invoices to hospital departments. |
| 2. Compiling individual doctor prescription or usage volumes (统方) | Representatives are strictly prohibited from collecting, tracking, or querying individual healthcare professional (HCP) usage data of specific devices, reagents, or consumables. |
| 3. Offering commercial kickbacks or personal benefits | Enforces a zero-tolerance ban on gifts, cash, equity, or personal favors. Notably, the prohibition extends to staff members' spouses, children, and other related persons. |
| 4. Tying donations or sponsorships to procurement volumes | Charitable donations, clinical research funding, and academic sponsorships must never be conditioned on, or tied to, the hospital's procurement volume of the manufacturer's products. |
| 5. Misrepresenting product efficacy or concealing adverse reactions | All technical promotions must align with the NMPA-approved instructions for use (IFU). Representatives must not exaggerate clinical benefits or omit known safety risks/adverse events. |
| 6. Accessing or misusing patient clinical data | Field personnel must not access patient medical records, diagnostic reports, or personal health files unless part of a formally approved clinical trial or authorized technical support procedure. |
| 7. Operating outside the authorized product scope or hospital regions | Representatives can only promote products for which they hold a valid, written authorization letter, and only within the specific hospitals and departments listed in that letter. |
| 8. Entering clinical departments without going through hospital reception | Field teams must register through the hospital's unified registration office. Direct, unannounced visits to clinical departments or private doctor offices are banned. |
| 9. Engaging in other illegal or non-compliant promotion activities | A catch-all clause capturing any activity that violates national anti-bribery, unfair competition, or healthcare administrative laws. |
Red Line 1: The Commercial-Academic Segregation
The most disruptive requirement for many multinational medtech companies is the prohibition on combining academic support with commercial sales execution.
In many device and IVD companies, field personnel act as "hybrid" representatives: they perform clinical case support in the operating room or laboratory, while also handling distributor price negotiations, purchase orders, invoice collection, and accounts receivable. Under the 2026 framework, this hybrid model is a direct compliance violation. Academic promotion personnel must be completely insulated from sales targets, payment collections, and invoice logistics.
Red Line 2: The Prohibition on "Tong Fang" (统方)
Tong Fang (统方) refers to the practice of compiling and analyzing the volume of drugs or medical consumables prescribed or used by individual physicians. Historically, this data was used to calculate individual sales commissions.
Under the 2026 Measures, any attempt by a representative to obtain individual physician usage data—either directly from hospital information systems or indirectly via pharmacy or equipment department staff—is a severe violation. It is critical to distinguish this from legitimate market analysis: tracking overall hospital-level procurement or regional sales volumes through distributors is permitted, but tracking physician-specific data is strictly prohibited.
MAH Principal Responsibility and the CSO Compliance Chain
A central pillar of the 2026 Measures is the codification of the Marketing Authorization Holder's (MAH) "principal responsibility" (主体责任). Article 4 and Article 11 state that the MAH is legally and administratively responsible for the behavior of all representatives promoting its products. This responsibility cannot be contractually outsourced or delegated.
The CSO and Distributor Audit Mandate
Many foreign manufacturers sell their products in China through a multi-tiered network of distributors and Contract Sales Organizations (CSOs). Historically, some manufacturers assumed that by outsourcing in-hospital promotion to local CSOs, they could insulate themselves from anti-bribery and commercial-bribery risks.
The 2026 Measures shut this loophole down. Under Article 8.2, if an MAH engages a third-party organization (such as a distributor or CSO) to conduct academic promotion, the MAH must enforce three specific controls:
- Capability Assessment: Conduct a formal, documented compliance and operational capability assessment of the CSO before onboarding.
- Written Management Agreement: Execute a detailed agreement specifying compliance obligations, behavior standards, and clear breach-of-contract liability terms.
- Per-Representative Authorization Letters: Issue individual, written authorization letters for every representative deployed by the CSO, detailing their identity, qualified product scope, and authorized hospitals.
If a CSO representative violates the Measures (e.g., by entering a clinical department without authorization or tracking physician usage data), the NMPA and joint agencies will hold the manufacturing MAH directly liable. Sanctions can include public blacklisting, suspension of product registrations, and increased frequency of unannounced audits—colloquially known as flight inspections. For manufacturers unfamiliar with these audits, the NMPA flight inspections and unannounced audits playbook provides a detailed guide on how the regulator audits local facilities.
The Broader Anti-Corruption Context: Two-High Judicial Interpretation II
The 2026 representative Measures do not operate in a vacuum. They are reinforced by a major criminal law update: the Interpretation (II) of the Supreme People's Court and the Supreme People's Procuratorate on Several Issues Concerning the Application of Law in the Handling of Criminal Cases of Bribery (Fa Shi [2026] No. 6), which took effect on May 1, 2026.
This judicial interpretation significantly lowers the threshold for prosecuting unit bribery (单位行贿)—the crime of a corporate entity offering bribes.
Historically, multinational companies operating in China could sometimes argue that a bribery incident was the isolated act of a "rogue employee" acting without corporate authorization. The Two-High Interpretation II establishes a "unit-will-plus-unit-benefit" standard. Under this standard, if the bribery is committed by an employee or agent (like a distributor/CSO) to obtain a commercial benefit for the company, and the company failed to implement effective compliance monitoring, the crime is attributed to the corporate entity itself.
For global compliance officers, this means that the absence of a robust monitoring system for distributors and CSOs is no longer just an administrative oversight—it is a direct contributor to corporate criminal liability in China.
Existing Provincial Rules for Device Representatives
While the national NMPA filing platform is not yet open to medical device representatives, manufacturers must comply with provincial-level rules that already regulate device field teams.
Several provinces and municipalities have proactively integrated medical device and IVD representatives into local hospital reception regulations. For example, the Fujian Provincial Health Commission and the Fujian Provincial Medical Products Administration jointly issued the Interim Provisions on the Reception of Medical Representatives by Staff of Public Medical Institutions in Fujian Province (闽卫规〔2024〕No. 2, effective March 1, 2024).
Unlike the national pharma-only Measures, the Fujian rules explicitly state that representatives hired by device enterprises to conduct in-hospital academic promotion of medical devices "follow these provisions" (遵照本规定执行), bringing medical device and IVD field personnel within their scope. Under these provincial rules:
- Device representatives must register and build a file with the hospital's designated management department (typically the pharmacy or equipment department), with at least one annual registration; unregistered representatives may not conduct in-hospital academic promotion.
- Representatives must provide proof of filing on the national platform, identity documents, and product authorization letters.
- Hospitals must operate appointment-based reception under a "Three-Fixed" reception discipline. Fujian's codified version is the "Three-Fixed, Two-Haved" (三定两有) standard — Fixed Reception Time (定接待时间), Fixed Reception Place (定接待地点), Fixed Reception Person (定接待人员), With Reception Process (有接待流程), and With Reception Record (有接待记录). Stricter provinces and individual hospitals have since moved up to the "Three-Fixed, Three-Haved" (三定三有, adding an advance appointment requirement: 定时、定点、定人；有预约、有流程、有记录) or even "Three-Fixed, Four-Haved" (三定四有, adding video monitoring). The Three-Haved tier is the recommended conservative preparation target for device manufacturers.
If a device representative is found in a clinical department without satisfying these conditions, the hospital is required to report the individual and their employing manufacturer to the local health commission and market supervision bureau. Similar local reception platforms and register systems are active in major metropolitan areas, including Shanghai and parts of Guangdong and Zhejiang provinces.
Medtech Preparation Roadmap: Low-Regret Actions
Because device-specific personnel rules are actively being drafted, multinational device and IVD manufacturers should use the current window to implement a low-regret compliance preparation program. The Medtech Compliance Preparation Flow:
Step 1: Role Audit & Segregation ➔ Step 2: CSO & Distributor Due Diligence ➔ Step 3: Standardize Authorization Letters ➔ Step 4: Align with Provincial Reception Rules ➔ Step 5: Implement Training & Ledger Systems
Step 1: Audit and Segregate Field Roles
Identify all personnel who enter Chinese hospitals on behalf of the manufacturer or its distributors. This includes sales managers, clinical application specialists, service engineers, and clinical trial monitors.
For clinical application specialists—who provide essential technical support during surgeries or laboratory runs—ensure their job descriptions, employment contracts, and performance incentive structures are completely decoupled from sales targets, invoicing, and payment collection. Maintain clear, documented evidence that their role is strictly technical and academic.
Step 2: Conduct CSO and Distributor Due Diligence
Review all active distributor and CSO agreements in China. Update agreements to include:
- Explicit compliance warranties reflecting the nine prohibited behaviors.
- Mandatory requirements for CSOs to conduct compliance training for their representatives.
- The manufacturer's right to audit the CSO’s representative records, training logs, and hospital activity ledgers.
- Clear termination rights if the distributor or CSO violates local hospital reception or anti-bribery regulations.
For a broader perspective on distributor governance, manufacturers can compare these requirements with the EU MDR importer and distributor obligations guide, which outlines how European law assigns post-market traceabilities and compliance duties across the distribution chain.
Step 3: Standardize Representative Authorization Letters
Develop a standardized template for representative authorization letters (授权书). The letter must be issued by the manufacturing MAH (or its legally authorized local entity) and must explicitly contain:
- The representative's full name, national ID number, and photo.
- The representative's employing entity (distributor or CSO).
- The specific product models and registration certificate numbers they are authorized to promote (refer to China NMPA device registration for details on registration certificates).
- The specific hospitals and departments they are authorized to visit.
- A clear validity period (recommended: maximum 12 months).
Step 4: Align with Provincial Reception Rules
Identify the provinces where the company's products are sold. For provinces with active representative reception systems (like Fujian), verify that all local distributor and manufacturer representatives have successfully completed hospital registration and are strictly adhering to the "Three-Fixed, Three-Haved" standard.
Step 5: Implement Traceability and Ledger (台账) Systems
Establish a centralized compliance ledger (台账) to record all in-hospital academic activities. The ledger should track:
- The date, time, and location of the activity.
- The names of the participating hospital staff and representatives.
- The specific academic content presented (e.g., presentation slides, clinical papers).
- A copy of the pre-activity hospital appointment confirmation.
Comparison: Pharma Measures vs. Medtech Preparation
The following table summarizes the legal differences between the active 2026 pharmaceutical representative rules and the recommended preparation standards for medical device and IVD manufacturers.
| Compliance Domain | Pharmaceutical Representatives (Effective Aug 1, 2026) | Medical Device / IVD Representatives (Prep Phase) |
|---|---|---|
| Legal Basis | NMPA Announcement No. 42 of 2026 (effective 2026-08-01). | Explicitly carved out; rules "formulated separately" (另行制定). |
| Filing Platform | Mandatory registration on the national pharmaceutical representative filing platform. | No national device filing platform active yet; must monitor local provincial registers. |
| Educational Threshold | Junior-college (大专) or higher degree in medicine, pharmacy, or related field. | Recommended internal standard of junior-college or higher; expected in future rules. |
| CSO Management | Strict capability review, written management agreement, and individual authorization required. | Recommended onboarding controls; crucial for mitigating corporate liability under unit bribery rules. |
| In-Hospital Conduct | Strict segregation of sales from academic work; zero-tolerance for Tong Fang. | Strict segregation recommended immediately; Tong Fang and commercial bribery already prohibited under SAMR rules. |
| Hospital Reception | Must follow "Three-Fixed, Three-Haved" standard national rules. | Must follow "Three-Fixed, Three-Haved" standard in provinces where local rules apply. |
Frequently Asked Questions
Are medical device sales representatives required to file on China's medical representative filing platform after 2026-08-01?
No. The national filing platform established under Announcement No. 42 of 2026 is designed exclusively for pharmaceutical representatives. Medical device and IVD representatives are currently carved out, as their specific management measures will be formulated separately.
When is China expected to issue device-specific representative or academic-promotion personnel rules?
While no official timeline has been published, regulatory analysts expect the NMPA and co-signing ministries to release draft medical device representative measures for public comment within the next 12 to 18 months. The final rules will likely mirror the structure and severity of the 2026 pharmaceutical measures.
Do the Measures' anti-bribery prohibitions on kickbacks to spouses and relatives apply to device companies now?
Yes. While the administrative filing requirements of the 2026 Measures do not yet apply to devices, the anti-bribery prohibitions (including targeting spouses, children, and relatives) reflect standard Chinese anti-corruption laws enforced by the Ministry of Public Security and SAMR. Offering benefits to relatives is prosecuted as commercial bribery under the Anti-Unfair Competition Law regardless of whether the industry is pharma or medtech.
What is the single highest-priority preparation step for a device manufacturer ahead of device-specific rules?
The highest-priority step is the segregation of clinical application specialists from commercial sales activities. Ensuring that technical and academic support staff do not carry sales targets, collect payments, or handle purchase invoices is the most effective way to mitigate compliance risks and align with the future direction of NMPA regulations.
Conclusion: Strategic Compliance Advantage
The 2026 Medical Representative Management Measures represent a major step in China's long-term campaign to clean up its healthcare supply chain. By replacing individual accountability with corporate MAH liability and mandating strict transparency across the distribution network, the Chinese government has made compliance a core commercial requirement.
For multinational medical device and IVD manufacturers, the current "formulated separately" carve-out is not a license to delay. Rather, it is a strategic window to build a clean, auditable, and resilient commercial model. Manufacturers that align their distributor networks, secure their representative authorizations, and isolate their technical support teams today will face minimal disruption when the final medical device measures are implemented.
Sources
Last reviewed 2026-06-30 against NMPA Announcement No. 42 of 2026 and the official Policy Interpretation. The Measures are effective 2026-08-01; device-specific representative rules remain to be formulated separately.
- NMPA Announcement No. 42 of 2026 (Official text)
National Medical Products Administration
https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20260507180422166.html - Policy Interpretation of the Medical Representative Management Measures
National Medical Products Administration
https://www.nmpa.gov.cn/xxgk/zhcjd/zhcjdyp/20260507174122178.html - NHC Medical Device Clinical Use Management Measures (Order No. 8)
National Health Commission
https://www.moj.gov.cn/pub/sfbgw/flfggz/flfggzbmgz/202103/t20210309_350144.html - Fujian Public Medical Institutions Staff Reception of Medical Representatives Interim Provisions (闽卫规〔2024〕No. 2, effective 2024-03-01)
Fujian Provincial Health Commission & Fujian Provincial Medical Products Administration
https://wjw.fujian.gov.cn/xxgk/zfxxgkzl/zc/bwgfxwj/202402/t20240207_6394215.htm - Two-High Judicial Interpretation (II) on Bribery Criminal Cases (Fa Shi [2026] No. 6)
Supreme People's Court & Supreme People's Procuratorate
Referenced from Supreme People's Court Gazetted Interpretations - China Strengthens Management of Medical Representatives
Arnold & Porter Client Advisory
https://www.arnoldporter.com/en/perspectives/advisories/2026/06/china-strengthens-management-of-medical-representatives - China Steps Up Anti-Corruption Enforcement with New Regulatory Frameworks
Morgan Lewis Law Flash
https://www.morganlewis.com/pubs/2026/05/china-steps-up-anti-corruption-enforcement-with-new-regulatory-frameworks - Impact of the New Medical Representative Management Measures on Distribution and Promotion Entities
Junhe Legal Updates
https://www.junhe.com/legal-updates/2988